Background : Rare cases of human glucocorticoid receptor (hGR α ) ( NR3C1) gene mutations have been described in the gemline or somatic state in Cushing ' s disease (CD). Aim : We describe a pediatric patient with CD with clinical evidence of partial glucocorticoid resistance (GR) due to the relative absence of stigmata of Cushing's syndrome (CS). Case description : A 14-year-old boy with slow growth and hypertension, but no other signs of CS was admitted for CD evaluation. Urinary free cortisol levels (UFC) were consistently 2-3-fold the upper normal range. Pituitary magnetic resonance imaging (MRI) revealed a 3 × 4 mm hypoenhancing lesion in the right side of the pituitary gland anteriorly
Introduction
Primary glucocorticoid resistance (GR) is a rare inherited disorder characterized by hypercortisolism without features of Cushing's syndrome (CS) (1) . The syndrome is characterized by increased secretion of cortisol, resistance to suppression by dexamethasone and other glucocorticoids, and the absence of the clinical stigmata of CS. Compensatory increases in the corticotrophin-releasing hormone (CRH), adrenocorticotrophin (ACTH), and cortisol production are also accompanied by increased secretion of glucocorticoid precursors with mineralocorticoid activity and increased adrenal androgens (2) . The increased cortisol concentrations appear to compensate adequately for the reduced sensitivity of the glucocorticoid receptor to cortisol. Patients with GR do not show signs or symptoms of overt clinical hypo-or hyper-cortisolism, with the exception of fatigue, which is the presenting sign in some patients (3) .
The molecular basis of GR has not yet been fully understood. Studies addressing the mechanism of resistance have shown that the human glucocorticoid receptor (hGR), the product of the NR3C1 gene, is the primary target of genetic alterations leading to resistance. The hGR is a transcription factor and a member of the nuclear receptor family. It has been localized to chromosome 5q31, contains a total of 9 exons, and is approximately 80 kb in size. Recently, two previously unidentifi ed exons have been reported to exist (called exon 1A and B) upstream from the originally defi ned exon 1 (now called exon 1C) (4) . There are two naturally occurring isoforms of the hGR gene, hGR α that is functional, and hGR β that has no hormone-binding ability. A third hGR mRNA has a higher expression level than the two other previously discovered messengers; it is 7.0 kb in length and contains exons 1 -8 and the entire exon 9, containing exon 9 α , the " J region, " and exon 9 β (5) . This mRNA is translated into hGR α . In addition, hGR mRNA may contain fi ve different versions of exon 1. Through the usage of the three different promoters, three different exons 1 can be transcribed (1A, B and C), and alternative splicing of exon 1A can result in three different versions of this exon (1A1, 1A2, 1A3) (4) . Upon glucocorticoid binding, the hGR α dimerizes and translocates to the nucleus, where it exerts its transcriptional activity by binding to its cognate genomic DNA sequences, such as the glucocorticoid response element.
The vast majority of glucocorticoid-resistant cells express low levels or defective forms of the hGR protein (6) . Mutations of hGR α have been described to impair one or more of the mechanisms of hGR α function, including affi nity for glucocorticoids (7) , affi nity for DNA (8) , number (9) , and translocation to the nucleus (10) . Inactivating mutations within the ligand-binding and DNA-binding domains, as well as deletions at the exon boundaries of the hGR α gene, have been described in kindreds and sporadic cases (11) . In addition, it has been identifi ed that fi ve polymorphisms in the hGR gene are not associated with a reduced sensitivity to glucocorticoids, which may be useful in analyzing whether loss of (part of) the hGR gene plays a role in glucocorticoid-resistant malignancies (12) . However, in many patients with clinical biochemical evidence of GR, no abnormalities in the hGR α gene have been observed (13) .
Pediatric pituitary adenomas are relatively rare and account for only 2.7 % of supratentorial tumors in children (14) . The majority of pituitary tumors is benign but remains clinically signifi cant because of tumor compression syndrome and hormone overproduction. Although the largest proportion of pituitary adenomas occur sporadically, about 5 % of pituitary adenomas occur in a familial setting, including multiple endocrine neoplasia type 1, Carney complex, and familial isolated pituitary adenomas (15) . The prevalence of clinically apparent pituitary adenomas is 3 -5 times higher than previously thought (16) . Apart from tumor suppression genes, genetic defects or changes in protein expression in signal transduction pathways (PKA, PKC, PI3K), cell cycle regulation (cyclin D), growth factors and their receptors (FGF, FGFR), chromosomal aneuploidity (PTTG), and oncogene activation (Ras) have all been linked to pituitary tumor formation (17) .
Although rare cases of NR3C1 mutations have been described in the germline or somatic state in patients with sporadic generalized GR who developed pituitary Cushing's disease (CD) years later (18) , thus far there are no reports of simultaneous pituitary adenoma in conjunction with GR in children. We report a unique pediatric patient with CD, clinical evidence of GR and absence of stigmata of CS, who had pituitary microadenoma without GR staining but did not have somatic or peripheral DNA NR3C1 coding sequence mutations.
Subject and methods

Protocol
For the purposes of this study, the patient and his family members were enrolled in protocol 97-CH-0076 for the genetic investigation of pituitary tumors; the patient and his family signed the appropriate consent and assent forms. The study and all relevant forms have been approved by the institutional review board of the National Institute of Child Health and Development.
Patient
The index subject was a 14-year-old male who was admitted for evaluation and treatment for suspected CS because he was found to have elevated serum cortisol and urinary-free cortisol (UFC) levels on multiple occasions. These were obtained in the course of investigation for short stature.
The patient had a sister with type 1 diabetes mellitus and celiac disease. There were no other known medical problems in the family. His mother had menarche at 12-and-half-years of age, and his father started puberty around the same time; both parents had average adult heights. The patient was in his usual state of good health until his investigation for short stature 2 years prior to diagnosis. He reported increased fatigue in the past year, although he did not report fever, polyuria, or polydipsia. He noticed some mild acne on his face and some mild facial fl ushing over the past year, but reported having no other rashes or lesions. He denied any ophthalmologic, ENT, respiratory, cardiovascular, gastrointestinal, or genitourinary complaints, yet did admit to an increase in muscle strain. From a neurologic standpoint, he reported headaches approximately once weekly at varied times of the day, which often responded to ibuprofen and rest. There was some associated nausea with the headaches but no emesis. Hematologic, lymphatic, endocrine, immunologic, and psychiatric reviews of systems were all negative. Physical examination failed to show any stigmata of CS. The patient was at the 5th centile for both height and weight. He had Tanner stage 4 for pubic hair, and testicular volume of approximately 2 mL bilaterally. There were < 10 comedones on the face and upper back.
Thyroid function tests were normal. Two 24-h UFCs measurements were 356 and 276 nmol/d, respectively (normal range 11.04 -154.56 nmol/d). Urine 17-hydroxysteroids were 40.57 and 34.77 μ mol/d (8.55 ± 5.52 μ mol/d). Table 1 shows the ovine CRH (oCRH) stimulation test results. Given some concern based on physical examination for GR, as opposed to isolated CS with the paucity of physical fi ndings of symptoms, with the exception of impaired linear growth and delayed puberty, 24-h cortisol and ACTH levels were measured every 20 min. The test was started at 4:00 pm and ACTH levels were in the 3.3 -3.3 pmol/L range (reference values 0.44 -1.98 pmol/L) Figure 2B ). The impression was that this was suspicious for a microadenoma, which was thought to be supported by the elevated UFC levels as well as the loss of diurnal variation of ACTH and cortisol. Both testes appeared normal on ultrasound with the left testis 1.1 × 2.3 × 1 cm, and the right testis 1.3 × 2.3 × 1 cm.
The patient underwent a graded dexamethasone suppression test ( Table 2 ). The decision was made to proceed with the excision of the pituitary microadenoma based on the MRI fi ndings of the pituitary adenoma, the loss of diurnal variation of ACTH and cortisol, and elevated UFC levels. The biopsy showed a pituitary adenoma, characterized by the proliferation of anterior lobe cells of similar morphology with reticulin breakdown and strong diffuse ACTH staining (Figure 3 .2) . Postoperative cortisol and ACTH serum levels are presented in Table 3 . Based on the results of a postoperative graded dexamethasone suppression test (Table 2) . It seemed that his GR likely required an 8-fold increase in serum cortisol with regards the general population with a normally functioning hGR. Results of a postoperative CRH testing are shown in Table 1 . Postoperative MRI of the pituitary revealed a small focus of non-enhancement measuring 3 × 1.5 mm in the anterior, inferior part of the right medial pituitary gland, which possibly represents a residual adenoma.
DNA analysis
DNA was extracted from peripheral blood leucocytes from the patient and his parents and from frozen tissue sample from the patient ' s pituitary tumor. The entire coding region of the NR3C1 was PCR amplifi ed using Taq DNA polymerase (Invitrogen Life Technologies, Inc., Carlsbad, CA, USA) on GeneAmp PCR System 9700 (PerkinElmer Applied Biosystems, Foster City, CA, USA). The primers used for PCR amplifi cation of genomic DNA were designed to encompass the NR3C1 coding exons and the exon-intron boundaries (Table 4 ) . Exon 2 was divided into four parts due to its length. The amplification conditions we used with these primers have been previously described (11, 19) . The PCR products were gel-purifi ed according to the manufacturer recommendations (Qiagen, minElute, Valencia, CA, USA) and sequenced in an automatic sequencer (3130xl Genetic Analyzer, Applied Biosystems, Foster City, CA, USA).
Results
Immunohistological fi ndings
The patient ' s pituitary adenoma showed reticulin breakdown and strong diffuse ACTH staining, as expected ( Figures  3.2B,C ). An MIB-1 staining revealed a proliferative rate of about 1 % and p53 immunostaining was negative. Using hGR antibody (ab52190-100 abcam, lot # 481755) hGR was not detected in this patient ' s adenoma and preserved border of intact pituitary tissue sections (Figures 3.2D,E) . In contrast to these sections and those of a negative control (unstained sections), normal pituitary tissues examined yielded cytoplasmic immunoreactivity (Figures 3.1D,E) . All sections of a pituitary ACTH producing adenoma tissue obtained from another patient (and also from a series of fi ve positive controls) demonstrated both cytoplasmic and nuclear immunolocalization of hGR (Figures 3.3D,E) .
Sequencing of the hGR α gene
At least two independent PCR-sequencing experiments of the NR3C1 entire coding region revealed no somatic (in the tumor) or genomic (in the peripheral lymphocytes) mutations.
Discussion
We describe a pediatric patient with little evidence of CS, despite the unequivocal presence of an aggressive ACTHproducing tumor and high UFCs. The patient underwent testing to determine the etiology of his elevated cortisol levels and underwent transsphenoidal surgery for the resection of a pituitary microadenoma.
Postoperatively, he had suppressed levels of cortisol and ACTH as would be expected after resection of a pituitary microadenoma. This patient did not have somatic or peripheral DNA NR3C1 coding sequence mutations. Possible explanations for this phenotype include low level somatic mosaicism for NR3C1 mutations or a mutation in another molecule that participated in hGR α -signaling.
Due to the varying degrees of end-organ insensitivity to glucocorticoids, the clinical picture of cortisol resistance may vary from fatigue, hirsutism, oligomenorrhea, infertility, obesity, and pubertas praecox to severe hypertension with hypokalemic alkalosis (20, 21) . Our patient reported increased fatigue in the past year; his only symptom of CD was (mild) short stature and delayed puberty, which can be found in children with CD (22, 23) .
Numerous actions of glucocorticoids are mediated by a set of at least 16 hGR isoforms forming homo-or hetero-dimers consisting of multifunctional domain proteins operating as ligand-dependent transcription factors that interact with many other cell signaling systems, including large and small G proteins (24) . Among the various hGR isoforms, a decline in the expression of hGR α may be associated with the development of resistance (25) . Evidence also shows that serine/argininerich SRp40 proteins may infl uence the alternative splicing of hGR pre-mRNA to regulate the ratio of hGR α to hGR β and that this effect is cell-dependent (26) . More recently, 15 missense, three non-sense, three frameshift, one splice site, and two alternative spliced mutations have been reported in the hGR α associated with GR, along with 16 polymorphisms (27) . Although the effects of glucocorticoid are mediated through the hGR α isoform, the presence of the four other isoforms that have altered DNA and ligand-binding domains may infl uence the response of a particular cell to glucocorticoids (25) .
Four novel hGR α transcripts have been recently identifi ed to have various deletions of exon 2 sequences arising from the hGR α 1A and 1B promoters, potentially affecting the hormone sensitivity or resistance (28) . The existence and tissue distribution of a novel splice variant, hGR Δ 313 -338, has also been reported; it is encoded by exon 2, representing a transcript variant encoding a smaller protein isoform with a predicted 26 residue (78 bp) deletion between the tau 1 domain and the DNA-binding domain encoded by exons 3 and 4 (29) . Therefore, we examined the patient ' s DNA for potential mutations in exon 2, coding solely for the fi rst transactivation domain, as well as exons 3 and 4, coding separately for the two zinc fi ngers in the DNA-binding domain.
No such mutations were found. Similarly, we did not fi nd any known or novel mutation sequencing exons 5 -9, coding for the C-terminus ligand-binding domain of the receptor. Such a mutant receptor (hGR α F737L) has been recently shown to cause generalized glucocorticoid resistance, because of decreased affi nity for ligand, marked delay in nuclear translocation, and abnormal interaction with the hGR-interacting protein 1 coactivator (30) . Screening showed a polymorphism at the beginning of exon 2 (silent mutation in codon 22/23) in two of fi ve patients without mutations in hGR α gene (12) . In a similar study, it has been reported that out of 12 GR patients, only two presented with a previously unidentifi ed hGR α gene polymorphism (exon 4 codon 477, exon 8 codon 679) (19) . In this study a " common " polymorphism at position 2430, AAT to AAC in exon 9 α , not resulting in a change in amino acid expression, has also been found in four of the 12 patients, a frequency similar to 30 % found in healthy controls (30) . In clinical and biochemical evidence of GR with no abnormalities demonstrated in the hGR α gene, other as yet defi ned alterations somewhere in the cascade of events started with ligand binding to the hGR α protein and fi nally resulted in the regulation of the expression of glucocorticoid responsive genes, or postreceptor defects or interactions with other nuclear factors, thereby forming the pathophysiologic basis of GR in these patients (13) . Therefore, the complexity of glucocorticoid biology lies more in the variety of receptor variants themselves rather than in the ligands to which they bind.
One of the most characteristic biochemical features of corticotroph tumors is their relative resistance to corticosteroid feedback. It has been hypothesized that clonal expansion of a single, genetically altered corticothroph cell might occur as a result of diminished negative feedback by cortisol in patients with GR due to a dominant negative hGR α gene mutation (18) . As in our patient, however, no mutations were detected in several ACTH-producing tumors (31) while the ratio hGR α / hGR β was relatively constant with an average of a 37-fold overexpression of hGR α (32) . Nonetheless, polymorphisms Human Development (NICHD), and in part by a sabbatical to Dr. G. Briassoulis by the University of Crete, Heraklion, Crete, Greece.
in the hGR α gene might confer a selective advantage to tumorigenesis in corticotropinomas (32) .
Our patient had an ACTH-producing pituitary adenoma with reticulin breakdown and strong diffuse ACTH staining. Immunohistochemical staining of a pituitary corticotropinoma in a patient with sporadic generalized GR revealed accumulation of p53 protein, indicating the presence of a putative somatic oncogenic mutation in the p53 gene in the tumor cells (29) . Given that the investigation of the lymphoblast and skin fi broblast cultures for p53 abnormalities did not show any aberration, a novel de novo germ line heterozygous missense mutation in the hGR gene (isoleucine 559 to asparagine 559) was revealed with strong dominant-negative activity, causing severe sporadic generalized GR preceding corticotroph adenoma formation. The latter has been attributed to the combined effects of chronic corticotroph hyperstimulation, decreased glucocorticoid negative feedback, and at least one subsequent somatic defect in the control of the cell cycle (29) . The cause of this rare combination of cortisol resistance and adenoma in our patient, who did not have peripheral DNA NR3C1 coding sequence mutations, awaits further investigation. Although the promoter regions and the introns of the gene have not yet been studied, possible explanations for this phenotype include low level somatic mos aicism for NR3C1 mutations or a mutation in another molecule that participated in hGR α -signaling.
